Shares of Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) have earned an average recommendation of “Buy” from the seven analysts that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $22.25.
A number of research firms recently issued reports on AQXP. Zacks Investment Research raised Aquinox Pharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research note on Thursday. Canaccord Genuity set a $22.00 target price on Aquinox Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday. BidaskClub raised shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. ValuEngine raised shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Cantor Fitzgerald set a $28.00 price objective on shares of Aquinox Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, May 9th.
Aquinox Pharmaceuticals (NASDAQ AQXP) traded up 0.53% during midday trading on Friday, reaching $13.17. The company had a trading volume of 28,620 shares. Aquinox Pharmaceuticals has a 1-year low of $8.76 and a 1-year high of $19.97. The company’s market capitalization is $308.48 million. The firm has a 50-day moving average of $14.49 and a 200 day moving average of $15.46.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its earnings results on Tuesday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.59). On average, equities research analysts forecast that Aquinox Pharmaceuticals will post ($2.15) EPS for the current year.
In related news, insider David Main sold 15,625 shares of Aquinox Pharmaceuticals stock in a transaction on Monday, June 5th. The shares were sold at an average price of $13.26, for a total value of $207,187.50. Following the transaction, the insider now owns 77,530 shares in the company, valued at approximately $1,028,047.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.70% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in Aquinox Pharmaceuticals by 6.6% in the second quarter. Vanguard Group Inc. now owns 282,483 shares of the company’s stock worth $3,974,000 after buying an additional 17,455 shares during the last quarter. Northern Trust Corp boosted its stake in Aquinox Pharmaceuticals by 3.3% in the second quarter. Northern Trust Corp now owns 83,207 shares of the company’s stock worth $1,171,000 after buying an additional 2,691 shares during the last quarter. Sphera Funds Management LTD. acquired a new stake in Aquinox Pharmaceuticals during the second quarter worth $874,000. Archon Partners LLC boosted its stake in Aquinox Pharmaceuticals by 44.0% in the second quarter. Archon Partners LLC now owns 18,000 shares of the company’s stock worth $253,000 after buying an additional 5,500 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Aquinox Pharmaceuticals by 16.5% in the second quarter. Bank of New York Mellon Corp now owns 23,260 shares of the company’s stock worth $327,000 after buying an additional 3,299 shares during the last quarter. 98.32% of the stock is currently owned by institutional investors and hedge funds.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.